Should I buy or sell Avadel Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVDL shares. View AVDL analyst ratings or view top-rated stocks .

What is Avadel Pharmaceuticals' stock price target for 2024?

5 equities research analysts have issued 1-year price targets for Avadel Pharmaceuticals' shares. Their AVDL share price targets range from $16.00 to $25.00. On average, they expect the company's stock price to reach $19.50 in the next year. This suggests a possible upside of 48.7% from the stock's current price. View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts .

How have AVDL shares performed in 2023?

Avadel Pharmaceuticals' stock was trading at $7.16 at the beginning of 2023. Since then, AVDL stock has increased by 83.1% and is now trading at $13.11. View the best growth stocks for 2023 here .

Are investors shorting Avadel Pharmaceuticals?

Avadel Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 4,770,000 shares, an increase of 19.3% from the October 31st total of 4,000,000 shares. Based on an average trading volume of 575,000 shares, the short-interest ratio is presently 8.3 days. View Avadel Pharmaceuticals' Short Interest .

When is Avadel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our AVDL earnings forecast .

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced its earnings results on Wednesday, November, 8th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.06. The company earned $7 million during the quarter, compared to analysts' expectations of $5.12 million. Avadel Pharmaceuticals's revenue for the quarter was up 3400.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.33) earnings per share.

What ETF holds Avadel Pharmaceuticals' stock ?

iShares Neuroscience and Healthcare ETF holds 8,651 shares of AVDL stock, representing 2.45% of its portfolio.

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I) , Bank of America (BAC) , Fossil Group (FOSL) , Ciena (CIEN) , AMC Entertainment (AMC) , Chaarat Gold (CGH) , Associated British Foods (ABF) , Apollo Global Management (APO) , Amarin (AMRN) and Cypress Semiconductor (CY) .

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include RTW Investments LP (7.99%), Gendell Jeffrey L (6.28%), Polar Capital Holdings Plc (5.03%), Vivo Capital LLC (4.58%), Wealth Effects LLC (2.70%) and Cowen AND Company LLC (2.62%). Insiders that own company stock include Eric J Ende, Geoffrey Michael Glass, Gregory J Divis, Linda Palczuk and Thomas S Mchugh. View institutional ownership trends .

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Avadel Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AVDL)

$13.11

+0.58 (+4.63%)

(As of 12/4/2023 ET)

Compare

Today's Range: $12.33
▼
$13.31
50-Day Range: $9.64
▼
$13.11
52-Week Range: $5.92
▼
$16.85

Volume: 873,401 shs
Average Volume: 707,362 shs
Market Capitalization: $1.18 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.50

Avadel Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 48.7% Upside
$19.50 Price Target
Short Interest: Bearish
5.31% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.86) to ($0.49) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

571st out of 952 stocks

Drug Manufacturers - Specialty & Generic Industry

1st out of 2 stocks

3.5

Analyst's Opinion

Consensus Rating
Avadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.50, Avadel Pharmaceuticals has a forecasted upside of 48.7% from its current price of $13.11.
Amount of Analyst Coverage
Avadel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.31% of the outstanding shares of Avadel Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Avadel Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.
Change versus previous month
Short interest in Avadel Pharmaceuticals has recently increased by 19.25%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Avadel Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Avadel Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVDL.

3.3

News and Social Media Coverage

News Sentiment
Avadel Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Avadel Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
6 people have searched for AVDL on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.00% of the stock of Avadel Pharmaceuticals is held by insiders.
Percentage Held by Institutions
71.23% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($1.86) to ($0.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Avadel Pharmaceuticals is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Avadel Pharmaceuticals is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

AVDL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AVDL Stock News Headlines

December 1, 2023 | americanbankingnews.com

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Sees Large Increase in Short Interest

November 14, 2023 | seekingalpha.com

Avadel: Lumryz Lights Up The Oxybate Market, Maintaining Buy Rating

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 13, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Avadel Pharmaceuticals (AVDL), Zymeworks (ZYME) and Aclaris Therapeutics (ACRS)

November 12, 2023 | seekingalpha.com

Assessing Avadel's Lumryz: Clinical Innovation Versus Economic Realities

November 10, 2023 | finance.yahoo.com

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q3 2023 Earnings Call Transcript

November 10, 2023 | markets.businessinsider.com

Avadel Pharmaceuticals Receives Buy Rating: Surpassing Revenue Expectations and Showcasing Robust Financial Health

November 8, 2023 | markets.businessinsider.com

Avadel Pharmaceuticals Sees Robust Uptake For Its Newly Approved Sleep Disorder Drug

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 8, 2023 | marketwatch.com

Avadel Pharmaceuticals ADRs Rise 19% on 3Q Revenue Growth of Lumryz Sales

November 8, 2023 | finance.yahoo.com

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 8, 2023 | morningstar.com

Avadel Pharmaceuticals PLC ADR AVDL

October 30, 2023 | finance.yahoo.com

Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 8

October 20, 2023 | finance.yahoo.com

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023

October 5, 2023 | finance.yahoo.com

Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit

September 26, 2023 | finance.yahoo.com

Avadel Pharmaceuticals PLC (AVDL): Is It Really Priced Right? An In-depth Exploration

September 25, 2023 | markets.businessinsider.com

Where Avadel Pharmaceuticals Stands With Analysts

September 23, 2023 | finance.yahoo.com

Avadel Pharmaceuticals plc's (NASDAQ:AVDL) institutional investors lost 7.6% last week but have benefitted from longer-term gains

August 22, 2023 | msn.com

Unusual Call Option Trade in Avadel Pharmaceuticals plc - ADR (AVDL) Worth $625.00K

August 22, 2023 | msn.com

Avadel Pharmaceuticals: A Resilient Buy; A Comprehensive Assessment Of Potential Prospects

August 13, 2023 | finance.yahoo.com

Geoffrey Glass Bought 13% More Shares In Avadel Pharmaceuticals

August 11, 2023 | finance.yahoo.com

Investing in Avadel Pharmaceuticals (NASDAQ:AVDL) five years ago would have delivered you a 182% gain

August 10, 2023 | msn.com

Piper Sandler Maintains Avadel Pharmaceuticals plc - ADR (AVDL) Overweight Recommendation

August 10, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)

August 9, 2023 | finance.yahoo.com

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

July 20, 2023 | seekingalpha.com

Avadel Pharmaceuticals: Winning Is Sweet

July 6, 2023 | msn.com

Avadel Pharmaceuticals plc - ADR (AVDL) Price Target Increased by 10.45% to 18.98

See More Headlines

Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AVDL
CUSIP: N/A
CIK: 1012477
Web: www.avadel.com
Phone: (531) 901-5201
Fax: 353-1526-1077
Employees: 41
Year Founded: 2015

Price Target and Rating

Average Stock Price Target: $19.50
High Stock Price Target: $25.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +48.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-137,460,000.00
Net Margins: N/A
Pretax Margin: -1,871.40%
Return on Equity: -306.46%
Return on Assets: -87.70%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.19
Quick Ratio: 3.09

Sales & Book Value

Annual Sales: $22.33 million
Price / Sales: 52.73
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.34) per share
Price / Book: -38.56

Miscellaneous

Outstanding Shares: 89,810,000
Free Float: 86,214,000
Market Cap: $1.18 billion
Optionable: Optionable
Beta: 1.55

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Gregory J. Divis Jr. (Age 56)
CEO & Director
Comp: $753.69k
Mr. Thomas S. McHugh (Age 58)
Senior VP & CFO
Comp: $526k
Mr. Richard J. Kim (Age 54)
Chief Commercial Officer
Comp: $548.44k
Mr. Jerad G. Seurer
General Counsel & Company Secretary
Mr. Gregory J. Davis (Age 58)
VP of Corporate and Business Development
Mr. Mark W. Elrod
Vice President of Sales
Ms. Angie Woods
Vice President of People & Culture
Dr. Jordan S. Dubow M.D. (Age 45)
Consultant
Comp: $727.93k
Dr. Jason M. Vaughn
Senior Vice President of Technical Operations
Ms. Jennifer Gudeman PharmD
Senior Vice President of Medical & Clinical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AVDL Stock Analysis - Frequently Asked Questions

Should I buy or sell Avadel Pharmaceuticals stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings or view top-rated stocks.
What is Avadel Pharmaceuticals' stock price target for 2024?: 5 equities research analysts have issued 1-year price targets for Avadel Pharmaceuticals' shares. Their AVDL share price targets range from $16.00 to $25.00. On average, they expect the company's stock price to reach $19.50 in the next year. This suggests a possible upside of 48.7% from the stock's current price.
View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts.
How have AVDL shares performed in 2023?: Avadel Pharmaceuticals' stock was trading at $7.16 at the beginning of 2023. Since then, AVDL stock has increased by 83.1% and is now trading at $13.11.
View the best growth stocks for 2023 here.
Are investors shorting Avadel Pharmaceuticals?: Avadel Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 4,770,000 shares, an increase of 19.3% from the October 31st total of 4,000,000 shares. Based on an average trading volume of 575,000 shares, the short-interest ratio is presently 8.3 days.
View Avadel Pharmaceuticals' Short Interest.
When is Avadel Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our AVDL earnings forecast.
How were Avadel Pharmaceuticals' earnings last quarter?: Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced its earnings results on Wednesday, November, 8th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.06. The company earned $7 million during the quarter, compared to analysts' expectations of $5.12 million. Avadel Pharmaceuticals's revenue for the quarter was up 3400.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.33) earnings per share.

What ETF holds Avadel Pharmaceuticals' stock ?: iShares Neuroscience and Healthcare ETF holds 8,651 shares of AVDL stock, representing 2.45% of its portfolio.
What other stocks do shareholders of Avadel Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).
Who are Avadel Pharmaceuticals' major shareholders?: Avadel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include RTW Investments LP (7.99%), Gendell Jeffrey L (6.28%), Polar Capital Holdings Plc (5.03%), Vivo Capital LLC (4.58%), Wealth Effects LLC (2.70%) and Cowen AND Company LLC (2.62%). Insiders that own company stock include Eric J Ende, Geoffrey Michael Glass, Gregory J Divis, Linda Palczuk and Thomas S Mchugh.
View institutional ownership trends.
How do I buy shares of Avadel Pharmaceuticals?: Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AVDL) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial